Skip to content

Study · Non-randomized trial · 1978

9 results

Effect of glucagon on aspirin-induced gastric mucosal damage in man.

Tarnawski A, Krause WJ, Ivey KJ

Gastroenterology1 Feb 1978Cited by 12 (Europe PMC)

PMID620896 (opens in a new tab)DOI10.1016/0016-5085(78)90804-1 (opens in a new tab)PepBankPUB-00620896
Publisher pagePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

  1. 01HumanNon-randomized trialPharmacokinetics

    In healthy volunteers, intravenous glucagon caused hyperglucagonemia.

    In plain wordsIn healthy volunteers, glucagon injection increased blood glucagon.

    Peptide
    Glucagon
    Outcome
    IncreaseHyperglucagonemia
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    2 mg · intravenousAs given in this study (human).

    Source sentences

    Summary
    Glucagon, 2 mg given intravenously, caused hyperglucagonemia, hypophosphatemia, hyperinsulinemia, increased blood glucose levels and gastric pH, as well as significant prolonged elevation of gastric potential difference.
    1 context sentence
    Summary · context
    The effect of glucagon on aspirin-induced damage to human gastric mucosa and its effect on gastric mucosal potential difference were studied in 27 healthy volunteers.
  2. 02HumanNon-randomized trialSafety outcome

    In healthy volunteers, intravenous glucagon caused hypophosphatemia.

    In plain wordsIn healthy volunteers, glucagon injection lowered blood phosphate.

    Peptide
    Glucagon
    Outcome
    DecreaseHypophosphatemia
    Study

    n: not reported in source

    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    2 mg · intravenousAs given in this study (human).

    Source sentences

    Summary
    Glucagon, 2 mg given intravenously, caused hyperglucagonemia, hypophosphatemia, hyperinsulinemia, increased blood glucose levels and gastric pH, as well as significant prolonged elevation of gastric potential difference.
    1 context sentence
    Summary · context
    The effect of glucagon on aspirin-induced damage to human gastric mucosa and its effect on gastric mucosal potential difference were studied in 27 healthy volunteers.
  3. 03HumanNon-randomized trialMechanism

    In healthy volunteers, intravenous glucagon caused hyperinsulinemia.

    In plain wordsIn healthy volunteers, glucagon injection increased blood insulin.

    Peptide
    Glucagon
    Outcome
    IncreaseHyperinsulinemia
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    2 mg · intravenousAs given in this study (human).

    Source sentences

    Summary
    Glucagon, 2 mg given intravenously, caused hyperglucagonemia, hypophosphatemia, hyperinsulinemia, increased blood glucose levels and gastric pH, as well as significant prolonged elevation of gastric potential difference.
    1 context sentence
    Summary · context
    The effect of glucagon on aspirin-induced damage to human gastric mucosa and its effect on gastric mucosal potential difference were studied in 27 healthy volunteers.
  4. 04HumanNon-randomized trialMechanism

    In healthy volunteers, intravenous glucagon increased blood glucose levels.

    In plain wordsIn healthy volunteers, glucagon injection increased blood glucose.

    Peptide
    Glucagon
    Outcome
    IncreaseBlood glucose
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    2 mg · intravenousAs given in this study (human).

    Source sentences

    Summary
    Glucagon, 2 mg given intravenously, caused hyperglucagonemia, hypophosphatemia, hyperinsulinemia, increased blood glucose levels and gastric pH, as well as significant prolonged elevation of gastric potential difference.
    1 context sentence
    Summary · context
    The effect of glucagon on aspirin-induced damage to human gastric mucosa and its effect on gastric mucosal potential difference were studied in 27 healthy volunteers.
  5. 05HumanNon-randomized trialMechanism

    In healthy volunteers, intravenous glucagon increased gastric pH.

    In plain wordsIn healthy volunteers, glucagon injection increased stomach pH.

    Peptide
    Glucagon
    Outcome
    IncreaseGastric pH
    Study

    n: not reported in source

    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    2 mg · intravenousAs given in this study (human).

    Source sentences

    Summary
    Glucagon, 2 mg given intravenously, caused hyperglucagonemia, hypophosphatemia, hyperinsulinemia, increased blood glucose levels and gastric pH, as well as significant prolonged elevation of gastric potential difference.
    1 context sentence
    Summary · context
    The effect of glucagon on aspirin-induced damage to human gastric mucosa and its effect on gastric mucosal potential difference were studied in 27 healthy volunteers.
  6. 06HumanNon-randomized trialMechanism

    In healthy volunteers, intravenous glucagon significantly elevated gastric potential difference for a prolonged period.

    In plain wordsIn healthy volunteers, glucagon injection produced a significant, prolonged increase in gastric electrical potential difference.

    Peptide
    Glucagon
    Outcome
    IncreaseGastric potential difference
    Study

    n: not reported in source

    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    2 mg · intravenousAs given in this study (human).

    Source sentences

    Summary
    Glucagon, 2 mg given intravenously, caused hyperglucagonemia, hypophosphatemia, hyperinsulinemia, increased blood glucose levels and gastric pH, as well as significant prolonged elevation of gastric potential difference.
    1 context sentence
    Summary · context
    The effect of glucagon on aspirin-induced damage to human gastric mucosa and its effect on gastric mucosal potential difference were studied in 27 healthy volunteers.
  7. 07HumanNon-randomized trialEfficacy outcome

    In healthy volunteers, glucagon 15 min before aspirin reduced damaged surface epithelial cells to 3.5%, versus 21 +/- 3% with aspirin alone.

    In plain wordsIn healthy volunteers, glucagon before aspirin reduced stomach cell damage compared with aspirin without glucagon pretreatment.

    Peptide
    Glucagon
    Outcome
    DecreaseSurface epithelial cell damage after aspirin
    Study

    n: not reported in source

    Comparator
    Aspirin without glucagon pretreatment
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    2 mg · intravenousAs given in this study (human).

    Measurements

    Damaged surface epithelial cells
    3.5%
    glucagon before aspirin
    Damaged surface epithelial cells
    21%
    aspirin alone; +/- 3

    Source sentences

    Summary
    Glucagon injection given 15 min before aspirin instillation effectively prevented surface epithelial cell damage, decreasing percentage of damaged cells to 3.5%.
    2 context sentences
    Summary · context
    Intragastric instillation of 600 mg of aspirin suspended in 100 ml of isotonic saline caused significant damage to 21 +/- 3% of surface epithelial cells and a marked reduction in gastric potential difference within 15 min of aspirin instillation.
    Summary · context
    The effect of glucagon on aspirin-induced damage to human gastric mucosa and its effect on gastric mucosal potential difference were studied in 27 healthy volunteers.
  8. 08HumanNon-randomized trialEfficacy outcome

    In healthy volunteers, glucagon did not prevent the aspirin-evoked decline in gastric potential difference.

    In plain wordsIn healthy volunteers, glucagon did not prevent the stomach electrical potential decline caused by aspirin.

    Peptide
    Glucagon
    Outcome
    No significant changeAspirin-evoked gastric potential difference decline
    Study

    n: not reported in source

    Comparator
    Aspirin without glucagon pretreatment
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    2 mg · intravenousAs given in this study (human).

    Source sentences

    Summary
    Glucagon did not prevent the drop in gastric potential difference evoked by aspirin, but did, however, prevent potential difference from falling below base line values after aspirin.
    1 context sentence
    Summary · context
    The effect of glucagon on aspirin-induced damage to human gastric mucosa and its effect on gastric mucosal potential difference were studied in 27 healthy volunteers.
  9. 09HumanNon-randomized trialEfficacy outcome

    In healthy volunteers, glucagon prevented gastric potential difference from falling below baseline after aspirin.

    In plain wordsIn healthy volunteers, glucagon kept stomach electrical potential difference from falling below baseline after aspirin.

    Peptide
    Glucagon
    Outcome
    IncreaseGastric potential difference below baseline after aspirin
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    2 mg · intravenousAs given in this study (human).

    Source sentences

    Summary
    Glucagon did not prevent the drop in gastric potential difference evoked by aspirin, but did, however, prevent potential difference from falling below base line values after aspirin.
    1 context sentence
    Summary · context
    The effect of glucagon on aspirin-induced damage to human gastric mucosa and its effect on gastric mucosal potential difference were studied in 27 healthy volunteers.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.